The International Osteoporosis Foundation (IOF) has welcomed the recently published paper European guidance for the diagnosis and management of osteoporosis in postmenopausal women from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Get the full story...
Most postmenopausal women who took the osteoporosis drug alendronate for 5 years and then stopped did not have an increased risk for nonvertebral fractures in the next 5 years, suggesting the medication has a lasting effect, according to a study in the December 27 issue of JAMA.
Read the full story
